Using the keyword GLP-1 and multiple organ dysfunction , five articles were identified
semaglutide 2.4 mg, 7.4%
The subcutaneous space contains small blood vessels but is not directly connected to major blood vessels in the same way as intravenous access, making air embolism from subcutaneous injection extremely unlikely
For instance, it healed transected muscles and counteracted NSAID toxicity without adverse effects.[24][25] Clinical Trials : A Phase I trial (NCT02637284) confirmed safety and pharmacokinetics in healthy volunteers, with no serious adverse events.[26] Phase II trials for ulcerative colitis showed encouraging results, with BPC-157 promoting remission.[27] A recent trial in inflammatory bowel disease patients reported tolerability and potential benefits.[28] The table below highlights select key studies: While robust, the reliance on animal models underscores the need for more large-scale human trials
Qi W, Zhang N, Korantzopoulos P, Letsas KP, Cheng M, Di F, Tse G, Liu T, Li G